Our expert for hiPSC-derived cardiac cells, as well as cell-based assays & services for drug safety and efficacy screenings
Ncardia has optimized the use of Pluricyte® Cardiomyocytes in combination with the Multiwell-MEA-System. Combining these technologies enables detailed electrophysiological detection of potential cardioactive and proarrhythmic effects of test compounds in a 96-well plate format.
Pluricyte® Cardiomyocytes in combination with the Multiwell-MEA-System provide a highly relevant in vitro assay platform to study the cardiac safety and efficacy profile of compounds during drug development.
You can find our recommendations on how to combine our cardiomyocytes with the Multiwell-MEA-System for electrophysiology measurements in the following User Guides:
Typical waveform of the extracellular field potential signal of Pluricyte® Cardiomyocytes obtained using the Multiwell-MEA-System from Multi Channel Systems.
Case studies were performed to assess the effects of cardioactive compounds on the electrophysiology of Pluricyte® Cardiomyocytes using the Multiwell-MEA-System (Multi Channel Systems). The effects of cardioactive reference compounds on the field potential duration, beat period, depolarization peak and conduction velocity are shown here.
Dofetilide induced a concentration-dependent increase of the field potential duration in Pluricyte® Cardiomyocytes
Dofetilide is a hERG channel blocker that is expected to prolong the repolarization, resulting in prolonged field potential duration (FPD) and ultimately proarrhythmic events. The induced concentration-dependent increase of the FPD in Pluricyte® Cardiomyocytes is shown here (first panel). At 100 nM, arrhythmias were observed (second panel).
You can find the complete study in our application note: